Phaseline

Targets › LILRB4

LILRB4 (Leukocyte immunoglobulin-like receptor subfamily B member 4): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Dec 2029.

Inhibitory receptor involved in the down-regulation of the immune response and the development of immune tolerance. Receptor for FN1. (UniProt, Q8NHJ6)

Open in Phaseline: the race on LILRB4, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Mabwell (Shanghai) Bioscience6MW5311
bispecific T cell engager antibody with bivalent binding to LILRB4 on tumor cells and mono
LILRB4, CD3EPhase 1AMLDec 2029

Conditions

AML (1)

Modalities

protein or peptide (1)

Companies

Mabwell (Shanghai) Bioscience (1)

Related targets

CD3E (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.